In focus
Latest feed
GLP-1 Drugs: The Unexpected Battle Against Addiction
Eli Lilly's Retatrutide Triumphs in Key Diabetes Trial, Poised to Reshape Obesity Treatment Landscape
The Final Word: Navigating Pharma's Powerhouse and Gold's Gleam in Today's Markets
Why Barclays Still Sees Eli Lilly as the Undisputed Champion in the Exploding GLP-1 Arena, Even as Rivals Crowd In
